RE:New Press Release - Kane Biotech Provides Investor Update Following FB Dermatology Acquisition AnnouncementThe video is helping with answering questions investors might have, not all questions are being answered but some, here's the key points -- feel free to add or comments on those if you see it differently;
1. FB Dermatoloy sales are a 'couple of millions' -- Euro, USD, CAD, that we don't know...
2. FB Dermatology sales force will be an obvious sales channel for the DermaKB product line and will expand the geographic area it is sold into;
3. The purchase price is not putting pressure on KNE financials situation;
4. Dr. Bellini is now a KNE shareholder -- this could be the best part of the deal we just made, time will tell;
5. The Revyve spray will be commercialized before year end -- this would be another good achievement;
6. The ACNE trail with UofMiami is going to start this QTR -- this would be another good news
The video helps a lot with better understanding the latest deal by shedding some lights on some details.It also confirms that two of the major short-term catalyst will effectively happen in Q4 of 2024 namely; the Revyve spray commercialisation and the starts of the UofMiami ACNE trials.
GLTA!